GURU.Markets stock price, segment price, and overall market index valuation
The company's share price 89bio Inc.
89bio is a biotech company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH). Its share price, like that of its competitors, is driven by news of clinical trials and hopes of creating the first approved drug for this massive market.
Share prices of companies in the market segment - Pharma metabolism
89bio is a biotech company developing drugs for the treatment of liver diseases and cardiometabolic disorders. We classify it in the Pharma Metabolism sector, and the chart below shows the overall performance of biotech companies in this field, where valuations are determined by clinical trial results.
Broad Market Index - GURU.Markets
89bio is a biopharmaceutical company developing drugs for the treatment of liver diseases and cardiometabolic disorders. Its focus on this niche makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how 89bio compares to it.
Change in the price of a company, segment, and market as a whole per day
ETNB - Daily change in the company's share price 89bio Inc.
Shares of 89bio, a biotech company developing drugs to treat liver diseases, are highly volatile. Change_co measures the market's reaction to clinical trial data. This metric is an important component of formulas on System.GURU.Markets that evaluate innovative companies in the metabolic disease sector.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
89bio, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ETNB, which focuses on liver disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
89bio is a biopharmaceutical company developing drugs for the treatment of liver diseases and cardiometabolic disorders. This is a highly competitive and risky field. The chart below shows the segment's volatility, helping to assess how typical 89bio's dynamics are for this niche.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization 89bio Inc.
89bio is a biotech company developing drugs to treat liver diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
89bio, Inc. is a clinical-stage biotech developing drugs for the treatment of metabolic steatohepatitis (MASH). Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this vast but complex area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
89bio is a clinical-stage biotech whose value reflects the hopes of developing new drugs. Its shares exhibit extreme volatility and are completely disconnected from economic cycles. The company's chart isn't about business, but about binary events: the success or failure of clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization 89bio Inc.
89bio, a biotech company developing drugs to treat liver and metabolic diseases, has sharp monthly fluctuations reflecting news about clinical trials of its lead candidate, which is typical for biotech companies in the R&D stage.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Biotech companies working on metabolic diseases are valued by the market based on the potential of their research. The chart below shows the overall fluctuations in this sector, reflecting both investor optimism and disappointment as research data is published. It provides context for assessing the risks of firms like 89bio.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
89bio is a biotech company developing drugs for metabolic diseases. Its shares, like those of other companies in the sector, move in sync with clinical trial news. Their price can fluctuate dramatically in a single day, ignoring overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization 89bio Inc.
89bio, Inc. is a clinical-stage biotechnology company developing drugs for the treatment of liver and metabolic diseases. Its weekly stock price is highly volatile and depends on news of clinical trial results, which can cause a sharp rise or fall in the stock price.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
89bio, as a clinical-stage biotech, exists in its own universe. Its weekly performance is 100% dependent on clinical trial news, not on general trends in the pharmaceutical industry. The chart clearly demonstrates these sharp, sector-neutral ups and downs, typical of biotechs on the cusp of breakthroughs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
89bio is a biotech company developing drugs to treat liver diseases. Its shares, like those of other biotechs, are driven by news of clinical trials. The chart will show how unique its path is and how independent it is of overall market sentiment.
Market capitalization of the company, segment and market as a whole
ETNB - Market capitalization of the company 89bio Inc.
89bio's market capitalization chart reflects investor expectations for its leading drug for the treatment of metabolic liver disease (MASH). As a biotech company with no revenue, its valuation depends entirely on clinical trial results. Any news, positive or negative, causes sharp fluctuations in the chart, as is typical for this sector.
ETNB - Share of the company's market capitalization 89bio Inc. within the market segment - Pharma metabolism
89bio, Inc. is a biotech company targeting the market for the treatment of metabolic diseases such as MASH. Its market capitalization is based on the potential of its lead drug, which has shown encouraging results in clinical trials.
Market capitalization of the market segment - Pharma metabolism
The graph below shows the total value of the biotech sector. 89bio specializes in treating metabolic diseases such as NASH (non-alcoholic steatohepatitis). The potential for this market is enormous, as this disease affects millions of people but currently has no approved treatment. 89bio aims to be the first to address this problem.
Market capitalization of all companies included in a broad market index - GURU.Markets
89bio is a biotech company developing drugs for the treatment of liver and metabolic diseases. Its market capitalization is based on the potential of its developments to combat common metabolic disorders. The chart below shows the importance of this segment in biotech.
Book value capitalization of the company, segment and market as a whole
ETNB - Book value capitalization of the company 89bio Inc.
89bio's foundation is its intellectual property, pegosafermin, a promising drug for the treatment of metabolic liver disease (NASH). The company's book value represents the capital it uses to conduct clinical trials. The chart shows how the company spends its funds on research, which, if successful, will create an invaluable intangible asset.
ETNB - Share of the company's book capitalization 89bio Inc. within the market segment - Pharma metabolism
89bio is a biotech company working on the treatment of metabolic diseases. The chart shows its share of actual R&D assets. These include its laboratories and scientific equipment, which serve as the physical basis for conducting clinical trials and developing new drugs.
Market segment balance sheet capitalization - Pharma metabolism
89bio, Inc. is a biotech company, which accounts for its low capital intensity. Its value lies in developing drugs for liver and metabolic diseases, not in its manufacturing capacity. Compared to the pharmaceutical sector as a whole, its "light" balance sheet is typical of companies in clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
89bio's assets are not drugs on the shelves, but promising molecules undergoing clinical trials for the treatment of liver and metabolic diseases. The company's balance sheet reflects the value of its intellectual property and research. The chart shows how much capital is invested in the fight against some of the most common diseases of our time.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - 89bio Inc.
89bio is a biotech company focused on treating metabolic diseases. Its market capitalization bears almost no resemblance to its cash-based balance sheet. Investors are buying into the hope that its lead drug will succeed in clinical trials. The chart is essentially a chart of faith in its science.
Market to book capitalization ratio in a market segment - Pharma metabolism
89bio is a biotech company focused on treating liver and metabolic diseases. Its market cap is a bet on the success of clinical trials. This chart shows how investors' hopes for a future blockbuster drive a valuation that bears almost no relation to the value of its laboratory assets.
Market to book capitalization ratio for the market as a whole
89bio is a biotech company developing drugs for liver and metabolic diseases. Its market capitalization reflects investor expectations for the success of clinical trials. This chart shows the significant premium the market places on scientific potential, even when the company has virtually no tangible assets.
Debts of the company, segment and market as a whole
ETNB - Company debts 89bio Inc.
89bio is a biotech company developing treatments for liver and metabolic diseases. The journey from a scientific concept to an approved drug requires significant financial investment. This chart shows how the company uses capital to fund the lengthy and expensive clinical trials of its lead candidates.
Market segment debts - Pharma metabolism
89bio, Inc. is a biotech company developing treatments for liver and metabolic diseases. Being in the clinical stage, it requires significant funding. This chart shows the company's chosen capital raising method—traditional equity or, less commonly, debt—which may indicate the stage and prospects of its development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio 89bio Inc.
89bio is a biotech company developing drugs for the treatment of liver diseases and cardiometabolic disorders. This chart shows its financial position at the clinical stage. The lack of debt and reliance on equity are typical for companies whose core business is conducting expensive and lengthy clinical trials.
Market segment debt to market segment book capitalization - Pharma metabolism
89bio is a biotech company developing drugs for metabolic diseases. The chart illustrates the leverage policy in the pharmaceutical development sector, where debt is often used to finance clinical trials. This allows us to understand how 89bio's financial strategy relates to the risks and timeframes inherent in this knowledge-intensive industry.
Debt to book value of all companies in the market
89bio is a biotech company financed primarily by equity. The chart illustrates the debt policy for the overall market. It clearly demonstrates the difference between financial models: while the overall market responds to interest rates, companies like 89bio depend on scientific breakthroughs and the appetite of venture capitalists.
P/E of the company, segment and market as a whole
P/E - 89bio Inc.
This chart for 89bio, Inc., a biopharmaceutical company working on treatments for metabolic diseases, is an assessment of its scientific potential. While its drugs are in development, the price-to-potential-future-revenue ratio is very high. The chart's movement reflects investor reactions to clinical trial results, which could either confirm or dash hopes.
P/E of the market segment - Pharma metabolism
This chart reflects the average valuation for the speculative biotech sector—the benchmark for 89bio. The entire sector is valued based on expectations for future drugs. For investors, this benchmark reflects the overall level of optimism in the industry. Against this backdrop, one can judge expectations for 89bio's developments in the treatment of metabolic diseases.
P/E of the market as a whole
89bio is a biotech company developing drugs for liver and metabolic diseases. Its future depends on the results of clinical trials. This chart shows how much risk investors are willing to take when investing in science. During periods of general optimism, they are willing to wait for success, but during downturns, they demand more compelling evidence from biotech companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company 89bio Inc.
89bio is a biotech company developing drugs for the treatment of liver and metabolic diseases. Its valuation is almost entirely dependent on clinical trial results. This chart reflects analysts' belief in the scientific and commercial potential of its lead drug candidate, which determines future, yet nonexistent, profit forecasts.
%20P%2FE%2089bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-89bio-Inc.&v=1772597010446 "Chart of the company's future (projected) P/E 89bio Inc.")
Future (projected) P/E of the market segment - Pharma metabolism
89bio is a biotech company developing therapies for liver and metabolic diseases such as NASH. Its valuation relative to other biotechs reflects expectations for its lead drug. A premium valuation may indicate that investors see it as a potential blockbuster in a huge and currently underserved market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772597010447 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
89bio is a biotech company developing drugs to treat liver and metabolic diseases. Its shares are a bet on the success of clinical trials. This chart shows the overall risk appetite of investors. When the market is optimistic, funding for non-revenue biotechs becomes more accessible, which is critical for 89bio's continued development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772597010457 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit 89bio Inc.
89bio is a biotechnology company developing treatments for liver and metabolic diseases, such as NASH. The financial metrics presented here primarily reflect investments in clinical trials. Positive trial results and potential drug approval are the company's primary drivers.
Profit of companies in the market segment - Pharma metabolism
89bio, Inc. is a biotech company developing drugs for the treatment of liver and metabolic diseases. This chart is a consolidated financial statement for companies in its core business. It helps assess the commercial viability of the metabolic disease field, or whether it remains a field of expensive clinical trials with uncertain outcomes.
Overall market profit
89bio is a biotech company developing drugs for the treatment of liver and metabolic diseases. Its journey is a long one, involving clinical trials and regulatory approvals. Macroeconomic cycles, visible on this chart, influence it only indirectly, through investor sentiment and the availability of capital for R&D.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company 89bio Inc.
89bio is a biotech company developing drugs for the treatment of liver and metabolic diseases. Its future profit forecast is an analyst's assessment of the likelihood of its lead candidate's success in clinical trials. The dynamics on the chart show the market's confidence in the company's ability to bring a marketable and commercially successful product to market.
%20profit%20of%20the%20company%2089bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-89bio-Inc.&v=1772597010461 "Graph of future (projected) profit of the company 89bio Inc.")
Future (predicted) profit of companies in the market segment - Pharma metabolism
89bio is a biotech company developing drugs for the treatment of liver diseases and cardiometabolic disorders. Their lead candidate targets nonalcoholic steatohepatitis (NASH). This chart shows revenue projections for this pharmaceutical segment. It provides context for assessing 89bio's potential in the vast but competitive metabolic disease market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772597010464 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
89bio, Inc. is a biopharmaceutical company developing drugs for the treatment of liver and metabolic diseases. The overall earnings forecast shown here influences investor sentiment in the biotech sector. Market optimism facilitates funding for the lengthy and capital-intensive clinical trials required to bring 89bio's products to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772597010466 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - 89bio Inc.
89bio is a biotech company developing drugs for metabolic diseases. It has no commercial revenue, so this metric reflects investors' faith in science. The valuation on the chart represents the potential future sales value of its drugs if they successfully complete clinical trials.
P/S market segment - Pharma metabolism
89bio is a biopharmaceutical company focused on treating liver and metabolic diseases, such as nonalcoholic steatohepatitis (NASH). This chart reflects the average valuation in the metabolic drug sector. It highlights investor expectations for companies developing drugs for large and currently unserved markets.
P/S of the market as a whole
89bio, Inc. is a biopharmaceutical company developing drugs for the treatment of liver and metabolic diseases. Its future cash flows depend on the success of clinical trials. This chart, reflecting overall market revenue estimates, provides a contrasting perspective on how investors value companies working at the forefront of science.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company 89bio Inc.
89bio is a biotech company developing therapies for liver and metabolic diseases, such as NASH. Its valuation is based on expected future sales of its lead drug candidate. The chart reflects investors' confidence in the success of clinical trials and the drug's commercial potential in a multi-billion dollar market.
%20P%2FS%2089bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-89bio-Inc.&v=1772597010488 "The graph of the company's future (projected) P/S 89bio Inc.")
Future (projected) P/S of the market segment - Pharma metabolism
89bio is a biotech company developing therapies for liver and metabolic diseases, such as non-alcoholic steatohepatitis (NASH). Its valuation is dependent on the success of clinical trials. This chart shows investor expectations for the future commercial success of its drugs compared to other companies in this competitive sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772597010490 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
This indicator demonstrates the market's faith in biotech innovation. For 89bio, which develops drugs for liver and metabolic diseases, it is an indicator of investment attractiveness. Investor optimism allows the company to fund clinical trials aimed at solving serious medical problems with enormous market potential.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772597010490 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales 89bio Inc.
89bio is a biopharmaceutical company developing drugs to treat liver and metabolic diseases, such as non-alcoholic steatohepatitis (NASH). This chart reflects revenue from collaborations and development funding. In the future, it will show revenue from sales of innovative drugs targeting one of the most common liver diseases.
Sales of companies in the market segment - Pharma metabolism
89bio is a biotechnology company developing therapies for liver and metabolic diseases, such as nonalcoholic steatohepatitis (NASH). This chart shows the market size of drugs for the treatment of metabolic disorders. 89bio's success in clinical trials is part of a global effort to combat this common disease.
Overall market sales
89bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for liver and metabolic diseases. Its market capitalization and ability to fund research are dependent on financial market sentiment. This general economic activity curve indirectly impacts the availability of venture capital for the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company 89bio Inc.
89bio is a biotechnology company developing therapies for liver and metabolic diseases, specifically nonalcoholic steatohepatitis (NASH). Future revenue is dependent on the success of clinical trials. This chart represents analysts' assessment of the likelihood of approval and commercial potential of the company's lead drug in a highly competitive market.
%20sales%20of%20the%20company%2089bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-89bio-Inc.&v=1772597010505 "Schedule of future (projected) sales of the company 89bio Inc.")
Future (projected) sales of companies in the market segment - Pharma metabolism
89bio is a biotechnology company developing drugs to treat liver and metabolic diseases, such as NASH. This forecast reflects expectations for the pharmaceutical segment of metabolic disorders. It demonstrates the huge potential market for effective treatments for these diseases that analysts see, which is important for 89bio's valuation.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772597010510 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
89bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for liver and metabolic diseases. Its valuation is determined by the potential of its investigational drugs. The overall economic environment, shown in this chart, influences the availability of capital for biotech companies to conduct expensive clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772597010514 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality 89bio Inc.
89bio is a biotech company developing drugs for the treatment of liver and metabolic diseases. This chart shows the financial picture at the clinical trial stage. Negative values represent strategic investments in research that could lead to the development of a sought-after drug and, consequently, high future profits.
Market segment marginality - Pharma metabolism
89bio, Inc. is a biopharmaceutical company developing treatments for liver and metabolic diseases. Being in the clinical stage, its financial metrics reflect intensive investment in R&D. This chart helps understand the company's cost structure and operating model compared to other biotech companies.
Market marginality as a whole
89bio is a biotechnology company developing drugs for the treatment of liver and metabolic diseases. This overall profitability curve is not a determining factor for the company. Its potential profitability is determined by the success of clinical trials and the ability to bring the drug to market for a large group of patients. Success here depends on science, not the state of the stock market.
Employees in the company, segment and market as a whole
Number of employees in the company 89bio Inc.
89bio is a biotechnology company developing treatments for liver and metabolic diseases. This chart shows the scientific and clinical teams leading their flagship drug through clinical trials. The growth in staff is directly related to the progress of the clinical program and preparation for potential commercialization.
Share of the company's employees 89bio Inc. within the market segment - Pharma metabolism
89bio develops treatments for liver and metabolic diseases. In this competitive field of biotechnology, the scientific team is a key asset. This chart shows the company's concentration of leading scientists and clinicians specializing in metabolic disorders, reflecting its scientific potential and focus on a specific therapeutic niche.
Number of employees in the market segment - Pharma metabolism
89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for liver and metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). This chart depicts employment in the metabolic pharmaceuticals segment, demonstrating how the fight against "diseases of civilization" is driving research and job creation.
Number of employees in the market as a whole
89bio is a biotech company developing treatments for liver and metabolic diseases. It exemplifies how science and medicine are creating high-paying jobs that require deep expertise. Growth in this sector not only addresses important healthcare issues but also creates an innovation cluster that is transforming the workforce.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company 89bio Inc. (ETNB)
89bio is a clinical-stage biotech company developing therapies for liver and metabolic diseases. This chart is a classic example of assessing scientific potential. The astronomical market capitalization per employee means the market is pricing in the success of future drugs being developed by a small team of scientists.
%20of%20the%20company%2089bio%20Inc.%20(ETNB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-89bio-Inc.-ETNB&v=1772597010551 "Chart of market capitalization per employee (in thousands of dollars) of the company 89bio Inc. (ETNB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
89bio (ETNB) is a clinical-stage biotech developing drugs for liver and metabolic diseases, specifically non-alcoholic steatohepatitis (NASH). This chart shows the industry average cost per employee. It helps estimate the market premium for their key drug (Pegozafermin) based on their small research staff.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772597010552 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
89bio, Inc. is a biopharmaceutical company developing treatments for liver and metabolic diseases. This chart reflects the average value the market assigns to one employee, highlighting the importance of intellectual capital and scientific potential in biotechnology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772597010553 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company 89bio Inc. (ETNB)
89bio is a biotech company developing therapies for liver and metabolic diseases. It is a clinical-stage company with no product revenue. This chart shows the net loss per employee (scientist, physician), reflecting the cost of R&D and investments in drug development.
%20Chart%2089bio%20Inc.%20(ETNB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-89bio-Inc.-ETNB&v=1772597010557 "Company Profit Per Employee (in thousands of dollars) Chart 89bio Inc. (ETNB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
89bio (ETNB) is an R&D biotech company (treating MASH, a liver disease). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772597010566 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
89bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for liver and metabolic diseases (NASH). Like other R&D biopharmaceuticals, this chart shows operating losses per scientist. This reflects the cost of advanced research and clinical trials leading to the development of a new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772597010576 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee 89bio Inc. (ETNB)
89bio is a biopharmaceutical company developing treatments for liver and metabolic diseases. This chart for a company in clinical trials reflects its path to commercialization. Current numbers may be low, but they lay the foundation for future growth once a successful drug reaches the market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-89bio-Inc.-ETNB&v=1772597010577 "Sales chart per company employee 89bio Inc. (ETNB)")
Sales per employee in the market segment - Pharma metabolism
89bio is a clinical-stage biotech company focused on treating liver and metabolic diseases (MASH). Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of 89bio's staff within the industry.
Sales per employee for the market as a whole
89bio is a clinical-stage biotech company developing treatments for liver and metabolic diseases. The company has no approved products or commercial revenue. Currently, this metric is zero. Investors evaluate the team's scientific potential and clinical trial prospects, not current sales performance.
Short shares by company, segment and market as a whole
Shares shorted by company 89bio Inc. (ETNB)
89bio is a biotech company developing treatments for metabolic diseases, primarily non-alcoholic steatohepatitis (NAS). This disease is a "graveyard" for many pharmaceutical companies due to its complexity. This chart shows how many investors are betting on 89bio's clinical trials to fail, given the failures of competitors in this field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-89bio-Inc.-ETNB&v=1772597010581 "Short Shares Chart for the Company 89bio Inc. (ETNB)")
Shares shorted by market segment - Pharma metabolism
89bio, Inc. is a biotech company developing therapies for liver and metabolic diseases, specifically nonalcoholic steatohepatitis (NASH). This chart shows the overall short position in the metabolism-focused biotech sector. Its rise reflects investor skepticism about the success of clinical trials in this complex area, which has seen many failures.
Shares shorted by the overall market
89bio (ETNB) is a clinical-stage biotech (liver disease). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives ETNB of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator 89bio Inc. (ETNB)
89bio (ETNB) is a biotech company developing treatments for liver and metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). The company's shares are sensitive to trial data. This chart shows these spikes: "overbought" (above 70) due to a successful trial phase or "oversold" (below 30) due to competitor failures or program delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-89bio-Inc.-ETNB&v=1772597010592 "RSI 14 indicator chart for the company's stock 89bio Inc. (ETNB)")
RSI 14 Market Segment - Pharma metabolism
89bio (ETNB) is a biotech company developing therapies for liver and metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). This chart measures the pulse of the Pharma/Metabolism sector. It helps distinguish ETNB's trial successes from overall overheating or overselling in the challenging NASH sector.
RSI 14 for the overall market
89bio (ETNB) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ETNB (89bio Inc.)
89bio, Inc. is a biopharmaceutical company developing treatments for serious metabolic liver diseases, primarily nonalcoholic steatohepatitis (NASH). This chart shows the average target price analysts are predicting for its lead drug in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ETNB-89bio-Inc.&v=1772597010595 "A chart showing analyst consensus forecasts for the expected stock price. ETNB (89bio Inc.)")
The difference between the consensus estimate and the actual stock price ETNB (89bio Inc.)
89bio (ETNB) is a biotech company developing therapies for metabolic diseases, primarily NASH (non-alcoholic steatohepatitis, fatty liver disease). This chart is an R&D barometer. It measures the gap between the price and the consensus target, reflecting how confident analysts are in the success of their drug candidates in this complex area.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ETNB-89bio-Inc.&v=1772597010595 "A chart showing the difference between the consensus forecast and the actual stock price. ETNB (89bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
89bio (ETNB) is a clinical-stage biotech focused on the treatment of liver disease (NASH) and lipid metabolism disorders. This chart shows analysts' overall expectations for the metabolism sector. It reflects whether experts believe in the success of fatty liver treatments, a huge untapped market.
Analysts' consensus forecast for the overall market share price
89bio (ETNB) is a clinical-stage biotech developing drugs for the treatment of liver diseases (NASH) and metabolic disorders. This is a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to fund unprofitable biotechs with high potential. Pessimism = risk aversion, and R&D capital dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index 89bio Inc.
89bio is a biotech company focused on treating metabolic diseases, primarily nonalcoholic steatohepatitis (NAS, fatty liver disease)—a huge but complex market. This chart represents the valuation of their lead drug candidate. Its performance is entirely dependent on the results of their clinical trials in this complex disease.
AKIMA Market Segment Index - Pharma metabolism
89bio (ETNB) is a clinical-stage biotech focused on metabolic diseases; the company is developing its candidate (Pegozafermin) for the treatment of NASH/MASH (liver disease). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does 89bio's highly competitive (NASH) R&D rate differentiate it from the average pharma company?
The AKIM Index for the overall market
89bio is a biotech company developing drugs for the treatment of liver diseases (MASH) and lipid disorders. It is a competitor in the hot field of metabolism. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative scientific story, fueled by trial data, compares to overall economic trends.
